Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

Original title: “An Alzheimer’s startup emerges with $175M in venture backing”

Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

Original title: “Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA”

Moderna said after a "Type A" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.

Original title: “FDA reverses course on Moderna’s flu vaccine”

Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.

Original title: “Korsana Joins Alzheimer's Amyloid Arena With $150M Debut, Next-Gen Antibody”

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Original title: “Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus”

CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.

Original title: “Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline”

Move expands iPSC‑derived retinal model portfolio and strengthens position in research

Original title: “Axol Bioscience acquires Newcells Biotech ophthalmology unit”

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.

Original title: “Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders”

With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.

Original title: “When Senior Leaders Are Asked To Carry Too Much”

PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.

Original title: “Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook”

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.

Original title: “Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations”

USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry production · SALT LAKE CITY--(BUSINESS WIRE)--#AvianInfluenza--Seek Labs, a private TechBio company building ... Seek Labs is a TechBio company approaching disease differently. We rebuilt the fundamental building blocks of disease response into a programmable system to detect, protect, and counter disease threats. SALT LAKE CITY--(BUSINESS WIRE)--#AvianInfluenza--Seek Labs, a private TechBio company building a programmable disease response platform to detect, protect, and counter disease threats, has been awarded $2 million from the U.S. As part of the award, Seek Labs will also collaborate with the Canadian Food Inspection Agency (CFIA). The award’s Principal Investigators are Douglas Gladue, Vice President of Veterinary Pharma at Seek Labs and Yohannes Berhane, Head of the Avian Disease Research Unit at CFIA. At the core of this system is an AI-powered intelligence layer that transforms raw biology into actionable data, informing two deployment layers across programmable therapeutics and molecular point-of-care diagnostics. The validated deployment layer insights feed back into the core to create a continuous, data-driven improvement loop, transforming how the world can detect and treat disease.

Original title: “Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency - BioSpace”

Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, analysts said.

Original title: “Ocular claims a win with eye drug data even as shares sink”

Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the protocol was developed with former FDA leaders.

Original title: “Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership”

Competing with giants like Takeda and Moderna, the plucky biotech believes it has unlocked a future with an easy, yearly oral vaccine.

Original title: “Does Vaxart Hold the Key to the Elusive Norovirus Vaccine?”

Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential Pharma’s...

Original title: “Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension”

Collaboration aims to speed access to challenging targets through an AI‑guided workflow

Original title: “Nuclera and leadXpro partner to accelerate structure‑based drug design”

As specialty medicines account for an increasing share of the drug pipeline, it makes sense for sponsors to support patients financially, emotionally and logistically.

Original title: “How to evaluate prospective diagnostic laboratory partners for your patient support program”

Navigating modular vs. integrated platforms—find the best path for your cell therapy program.

Original title: “Selecting the optimal cell therapy manufacturing platform”

Shift Toward One Time Curative ... symptomatic treatments. Industry Developments Expansion of Clinical Stage Gene Therapy Pipelines: Multiple therapies targeting neuromuscular, metabolic, and hematologic rare diseases are progressing through trials.... Shift Toward One Time Curative Treatments: Gene therapy offers long term or permanent therapeutic benefit compared with chronic symptomatic treatments. Industry Developments Expansion of Clinical Stage Gene Therapy Pipelines: Multiple therapies targeting neuromuscular, metabolic, and hematologic rare diseases are progressing through trials. Press release - DataM intelligence 4 Market Research LLP - Gene Therapy for Rare Disease Market to Reach US$ 24.54 Billion by 2033 at 26.5% CAGR; North America Leads with 45% Share - Key Players: Novartis AG, Sarepta Therapeutics, Inc., bluebird bio, Inc. - published on openPR.com Asia Pacific - Holds 18% share: Expanding biotech innovation, government funding, and increasing clinical trial activity accelerate adoption. Latin America - Holds 4% share: Gradual improvement in rare disease diagnosis and access to advanced therapies supports emerging demand. The Gene Therapy for Rare Disease Market was valued at USD 3 01 billion in 2024 and is projected to reach USD 24 54 billion by 2033 expanding at a CAGR of 26 5 during the forecast period from 2025 ...

Original title: “Gene Therapy for Rare Disease Market to Reach US$ 24.54 Billion by 2033 at 26.5% CAGR; North America Leads with 45% Share - Key Players: Novartis AG, Sarepta Therapeutics, Inc., bluebird bio, Inc.”